Michele Hamilton, MD
Advanced Heart Failure and Transplant Cardiology · Beverly Hills, CANPI 1659390227
Payments from drug & device makers
Across 30 payments — averaging $556.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$17K
- Medtronic$106
- Gilead$18
- Kestra Medical Technology Services, Inc.$13
- EMD Serono, Inc.$12
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2
What the payments were for
- Consulting fees$6,00036%
- Speaking & faculty fees$9,45057%
- Travel & lodging$6844%
- Food & beverage$5753%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 25 | $16,558 |
| Medtronic | 1 | $106 |
| Gilead | 1 | $18 |
| Kestra Medical Technology Services, Inc. | 1 | $13 |
| EMD Serono, Inc. | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$9,450
- HeartMate$6,000
- HeartMate PHP$468
- HeartMate 3 Left Ventricular Dev$164
- HeartWare HVAD$106
How this compares
$16,709 in reported general payments places this provider in the 40th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $92,541 |
| EntrestoSacubitril/Valsartan | 48 | $68,407 |
| XareltoRivaroxaban | 28 | $41,896 |
| Repatha SureclickEvolocumab | 25 | $28,539 |
| FarxigaDapagliflozin Propanediol | 29 | $26,036 |
| JardianceEmpagliflozin | 14 | $22,070 |
| Rosuvastatin Calcium | 209 | $3,884 |
| Metoprolol Succinate | 164 | $2,950 |
| Atorvastatin Calcium | 137 | $2,098 |
| Carvedilol | 91 | $1,313 |
| Amlodipine Besylate | 126 | $1,291 |
| Potassium Chloride | 34 | $1,070 |
| Nitroglycerin | 19 | $1,015 |
| Ezetimibe | 31 | $1,004 |
| Losartan Potassium | 55 | $873 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Beverly Hills
- Antoine HageBeverly Hills$907K
- Jignesh PatelBeverly Hills$576K
- Dael GeftBeverly Hills$85K
- David ChangBeverly Hills$57K
- Jaime MoriguchiBeverly Hills$48K
- Ronald WittelesStanford$4.1M
- James Heywoodla Jolla$2.1M
- Eldrin LewisStanford$1.8M
- Richard WrightSanta Monica$1.7M
- Eric AdlerSan Diego$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.